SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1

Article Biochemistry & Molecular Biology

The Smad4-MYO18A-PP1A complex regulates beta-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma

Jialiang Liu et al.

Summary: This study revealed that coexpression of Smad4 and MYO18A is a favorable prognostic indicator for iCCA and pCCA, suppressing CCA proliferation and metastasis by regulating beta-catenin phosphorylation and intracellular localization.

CELL DEATH AND DIFFERENTIATION (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling Axis

Wenjing Xiong et al.

Summary: Loss of Smad4 enhances immunogenicity of PDAC tumors by promoting DNA damage and stimulating STING-mediated interferon signaling, leading to activation of the immune system for tumor control.

ADVANCED SCIENCE (2022)

Add to Collection

Review Immunology

Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers

Yun-cheng Li et al.

Summary: Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, originate from the biliary epithelium and have a poor prognosis. Surgery is the only choice for cure in the early stage of disease, and early diagnosis could significantly improve the prognosis of patients. Bile components are closely related to the occurrence and development of biliary tract tumors and may be applied as biomarkers for BTCs.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Recent advances of immunotherapy for biliary tract cancer

Alessandro Rizzo et al.

Summary: Although immunotherapy has revolutionized the treatment landscape of several hematological and solid tumors, the role of ICIs and immune-based combinations in advanced BTC is still unclear. Despite ICI monotherapy has reported limited efficacy in this setting, the durable responses observed in sporadic cases suggest that testing patients for MMR, MSI, TMB, and PD-L1 expression is warranted. Results of currently ongoing trials are highly awaited.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways

Tianli Chen et al.

Summary: This study demonstrates that WDR5 interacts with c-Myc in cholangiocarcinoma (CCA), leading to increased HIF-1 alpha expression and stability, thereby promoting tumor metastasis and invasion.

MOLECULAR THERAPY (2021)

Add to Collection

Article Cell Biology

Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression

Yue Wang et al.

Summary: ALDH3B2 promotes tumor proliferation and metastasis in CCA by regulating the expression of ITGB1 and upregulating its downstream signaling pathway. The double-positive expression of ITGB1 and ALDH3B2 serves as a better prognostic biomarker of CCA.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses

Jihoon G. Yoon et al.

Summary: This study identified predictive molecular features of chemotherapy and immunotherapy responses in advanced BTCs using clinical sequencing platforms. The results offer an intuitive framework to guide treatment based on the tumors' molecular features.

HEPATOLOGY (2021)

Add to Collection

Review Oncology

Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Yue Wang et al.

Summary: The article summarizes the latest advances in antiangiogenic therapy for biliary tract cancers, focusing on the molecular mechanisms and therapeutic effects, while highlighting the uncertainty surrounding the effectiveness of antiangiogenic therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Article Cell Biology

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

Marine Bruand et al.

Summary: This study investigates mechanisms of inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss leads to transcriptional reprogramming and inflammation involving type I interferon (IFN) and STING. Genetic deletion or methylation of DNA-sensing/IFN genes or CCL5 chemokine can attenuate T cell inflammation. Tumor-intrinsic STING elimination reduces neoangiogenesis and reverses therapeutic resistance to immune checkpoint blockade. VEFG-A blockade synergizes with STING loss and immune checkpoint blockade to control tumor growth in HRD cancers.

CELL REPORTS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The STING1 network regulates autophagy and cell death

Ruoxi Zhang et al.

Summary: STING1 plays a crucial role in infection, inflammation, and immunity by activating transcription factors, as well as regulating autophagy and various cell death modalities. Understanding the signaling pathways of STING1 may provide insights into new therapeutic targets.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Oncology

Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer

Jinyang Li et al.

Summary: This study identifies lysine demethylase 3A (KDM3A) as an epigenetic regulator that affects the response to immunotherapy in pancreatic ductal adenocarcinoma by modulating the expression of epidermal growth factor receptor (EGFR) through Krueppel-like factor 5 (KLF5) and SMAD family member 4 (SMAD4). Inhibition of EGFR can reshape the immune microenvironment, offering a potential immunotherapy-sensitizing strategy for PDA.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology